Dublin headquartered Broadlake sells its majority stake in Irish skincare company Vita Liberata

This transaction marks Broadlake’s second exit in as many months following the €68m sale of Merlyn Industries to Norcros Plc in November 2017.

January 5th 2018 – Vita Liberata, the international skincare and self-tan brand, has been acquired by US based Crown Laboratories Inc., a fully-integrated specialty pharmaceutical company focused in dermatology with the backing of New York private investment firm Hildred Capital Partners.

Broadlake is a private investment company that typically invests €2-10m in established and growing businesses. Broadlake invested in Vita Liberata in 2012 to accelerate the international growth of the business, supporting its successful expansion into the North American market.

“We backed an ambitious team in 2012 and over the last five years have supported them during a period of phenomenal growth.  Over this time the company has successfully developed its product ranges, brands, channels and international reach.  We view Crown as an ideal partner to support the company on the next stage of its growth and development.  We wish the Vita Liberata team every success in the future,” said Pete Smyth, Broadlake Founder and Chief Executive.

Founded in 2003 by EY Entrepreneur of the Year finalist Alyson Hogg, Vita Liberata was the first completely non-toxic tanning brand, with a collection of odourless products free from parabens, perfume and alcohol.  Vita Liberata products employ the company’s proprietary Advoganic™ Technology, which combines cutting edge skin chemistry with highly potent organic botanicals. The technology fully releases the premium ingredients’ potential, enabling skincare benefits that are superior to those found in formulas using traditional cosmetic chemicals.

The brand has a powerful celebrity fanbase which include Hollywood icons Emma Watson, Sofia Vergara and Alicia Keys. Vita Liberata’s award-winning collection is sold in premium retailers across the US and Europe, and it is the self-tanner of choice for the world’s top spas including George V Paris, St Regis, Viceroy, Ritz-Carlton and Burj Al Arab.  Ms. Hogg will stay on as President of Consumer Brands for Crown Laboratories.

“Crown and Hildred have a genuine understanding of the suncare market and a very impressive vision for the Vita Liberata brand. We are thrilled to partner with them to leverage Crown’s strong positioning within the dermatology space and advance our mission of making self-tanning a viable alternative to sun exposure for all,” said Alyson Hogg.

“We believe the Vita Liberata product line and its strength in premium retail is a terrific complement to Crown’s Blue Lizard sunscreen brand and builds on Crown’s consumer healthcare products strategy in the dermatology space,” said Jeff Bedard, Crown Laboratories President and CEO. “Alyson and her entire team have done a remarkable job disrupting the self-tanning space, and we look forward to welcoming them to the Crown family. We will work together to continue to provide high-quality products that are at the forefront of skincare innovation.”

“Hildred’s goal for Crown is to build value by providing the company with the flexibility needed to foster organic growth,” said Hildred Partner, David Solomon. “With a distinctive portfolio and an impressive track record of growth, Vita Liberata is a very exciting opportunity and a natural fit with Crown.”


Los Angeles and New York based investment bank, The Sage Group LLC served as exclusive financial advisor to Broadlake and Vita Liberata, Tughans served as legal advisors, and EY served as due diligence and tax advisors.

Centerview Partners served as financial advisor to Crown Laboratories, and Lowenstein Sandler and A&L Goodbody served as its legal advisors.

Financial terms of the transaction were not disclosed.


About Broadlake

Broadlake is a Dublin headquartered private investment company that typically invests €2-10m in established and growing businesses. The Broadlake Team is focused on working with Entrepreneurs where the opportunity exists to help them significantly scale their businesses. Broadlake’s current portfolio includes 2468 Group the acquisitive Office Services business, TTM the International Healthcare Recruitment & Services company and Conveyortek the Northern Irish based Engineering company.

Website:              www.broadlake.ie

Twitter:                @wearebroadlake @broadlakepete


About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company, focused in dermatology, and committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories is an innovative company, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown Laboratories’ rapid growth. Crown Laboratories’ prescription portfolio includes key branded products AlaScalp, AlaQuin, Daxbia and Dermasorb HC & TA Kits. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.


About Hildred Capital Partners

Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.


For further Broadlake information contact:
Geraldine O’Neill PR        +353 87 686 2995 / +353 1 598 9400